Impact of Thiazides and Fluoropyrimidines Interaction on ...

연구 요약

Impact of Thiazides and Fluoropyrimidines Interaction on Myelotoxicity and Other Adverse Events in Real-World Practice: A Retrospective Cohort Study.

Cancer medicine 학술지에 발표된 이 연구는 Ronda-Roca G, Porcel-Maleno J, Lobo-Palomar M 외 연구팀이 수행하였습니다.

핵심 내용

INTRODUCTION: The European Summary of Product Characteristics (SmPC) for 5-FU warns of significant granulocyte decline when combined with thiazides, cyclophosphamide, or methotrexate, based on a 1981 cohort of 14 patients. Despite limited evidence, drug-interaction checkers still flag this risk. We conducted a retrospective cohort study to compare myelotoxicity in patients receiving fluoropyrimidines with or without thiazides. Secondary objectives included assessing clinical relevance and overall safety. METHODS: A retrospective, single-center observational study was performed using electronic health records. The cohort included colorectal cancer patients treated with capecitabine or capecitabine-oxaliplatin, with a maximum of one prior chemotherapy line. Myelotoxicity was defined using local laboratory thresholds. Clinical relevance was assessed through predefined adverse events (AEs). All AEs and lab data were collected up to 1 month after chemotherapy completion. RESULTS: We included 192 patients (mean age 68.6 ± 13 years; 61.5% male); 37 (19.3%) were on thiazides at treatment start. Baseline characteristics were largely comparable between groups, although thiazide users were older. Median follow-up was 126 days (IQR: 84-158). Hemoglobin declined significantly in thiazide users at 1-3 months (-0.3 vs. +0.11 g/dL; p = 0.006) and > 6 months (-2.63 vs. -0.75 g/dL; p = 0.002). Other hematologic parameters showed no significant differences.

일반인을 위한 해석

이 연구는 약물 또는 영양제의 안전한 사용에 관한 과학적 근거를 제공할 수 있습니다. 다만, 개별 연구 결과만으로 일반화하기는 어려우며, 추가적인 연구가 필요할 수 있습니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41755543)